The Canada Pension Plan Investment Board (CPPIB), joins Fusion Pharmaceuticals and has committed to an investment of up to US$20 million, adding to the US$105 million Series B that was announced in April 2019.
“CPPIB’s investment reflects strong support for Fusion’s platform technology and people and demonstrates momentum in the radiopharmaceutical industry. The additional capital provides opportunities for Fusion to accelerate our growth plans and our pipeline of novel and combination therapy assets that can deliver effective and personalized radiation therapies to cancer patients.” – Chief Executive Officer John Valliant.
Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted alpha therapeutics to treat cancer. Using its proprietary Fast-Clear™ Linker Technology platform, Fusion attaches medical isotopes to targeting molecules creating novel, next-generation cancer treatments.
Read the full story here: Fusion Pharmaceuticals Announces Investment from Canada Pension Plan Investment Board (CPPIB)